Novel Agents Targeting VEGFRs and c-MET: The Results in mCRC Patients

Speaker: Heinz-Josef Linz

H-J Lenz explains the results from study that indicate neuropilin 1 may have both prognostic and predictive value in metastatic colorectal cancer (mCRC) patients treated with Angiogenesis inhibitors. Besides progress in inhibiting angiogenesis signalling with a plethora of targeted agents, he elaborates complexity in inhibiting c-MET signalling in mCRC and illustrate it with results from studies presented at ESMO World GI Congress 2015.

Discussion point

  • Results from Neuropilin 1 (NRP1) analysis in a subgroup of patients with metastatic colorectal cancer (mCRC) who benefit from tivozanib + mFOLFOX6 compared to bevacizumab + mFOLFOX6. (abstract O-0007)
  • Results of Phase II study of tivantinib (ARQ 197) in combination with cetuximab in EGFR inhibitor-resistant, MET-high, KRAS Wild-type  mCRC (abstract O-0008)
  • Progress in inhibiting angiogenic signalling pathway in mCRC
  • Complexities in targeting the c-MET pathway in mCRC